Pre/Post-Treatment Dynamic of Inflammatory Markers Has Prognostic Value in Patients with Small Hepatocellular Carcinoma Managed by Stereotactic Body Radiation Therapy

References

• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2 ):115–132. doi:10.3322/caac.2133826808342
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2 ):87–108. doi:10.3322/caac.2126225651787
   PubMed Web of Science ®Google Scholar
• Zhou J, Sun HC, Wang Z, et al. Guidelines for diagnosis and treatment of primary liver cancer in China (2017 Edition). Liver Cancer. 2018;7(3 ):235–260. doi:10.1159/00048803530319983
   PubMed Web of Science ®Google Scholar
• Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11(4 ):317–370.28620797
   PubMed Web of Science ®Google Scholar
• Truty MJ, Vauthey JN. Surgical resection of high-risk hepatocellular carcinoma: patient selection, preoperative considerations, and operative technique. Ann Surg Oncol. 2010;17(5 ):1219–1225. doi:10.1245/s10434-010-0976-520405326
   PubMed Web of Science ®Google Scholar
• Zeng ZC, Seong J, Yoon SM, et al. Consensus on stereotactic body radiation therapy for small-sized hepatocellular carcinoma at the 7th Asia-Pacific Primary Liver Cancer Expert Meeting. Liver Cancer. 2017;6(4 ):264–274. doi:10.1159/00047576829234630
   PubMed Web of Science ®Google Scholar
• Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013;13(11 ):759–771. doi:10.1038/nrc361124154716
   PubMed Web of Science ®Google Scholar
• Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11 ):e493–e503. doi:10.1016/S1470-2045(14)70263-325281468
   PubMed Web of Science ®Google Scholar
• Fan W, Zhang Y, Wang Y, Yao X, Yang J, Li J. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of survival and metastasis for recurrent hepatocellular carcinoma after transarterial chemoembolization. PLoS ONE. 2015;10(3 ):e119312.
   Web of Science ®Google Scholar
• Da FL, Barroso-Sousa R, Bento AS, et al. Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib. Med Oncol. 2014;31(11 ):264. doi:10.1007/s12032-014-0264-525273866
   PubMed Web of Science ®Google Scholar
• Chu MO, Shen CH, Chang TS, et al. Pretreatment inflammation-based markers predict survival outcomes in patients with early stage hepatocellular carcinoma after radiofrequency ablation. Sci Rep. 2018;8(1 ):16611. doi:10.1038/s41598-018-34543-z30413724
   PubMed Web of Science ®Google Scholar
• Tajiri K, Baba H, Kawai K, et al. Neutrophil-to-lymphocyte ratio predicts recurrence after radiofrequency ablation in hepatitis B virus infection. J Gastroenterol Hepatol. 2016;31(7 ):1291–1299. doi:10.1111/jgh.1328726729319
   PubMed Web of Science ®Google Scholar
• Liao W, Zhang J, Zhu Q, et al. Preoperative neutrophil-to-lymphocyte ratio as a new prognostic marker in hepatocellular carcinoma after curative resection. Transl Oncol. 2014;7(2 ):248–255. doi:10.1016/j.tranon.2014.02.01124704092
   PubMed Web of Science ®Google Scholar
• Li C, Wen TF, Yan LN, et al. Postoperative neutrophil-to-lymphocyte ratio plus platelet-to-lymphocyte ratio predicts the outcomes of hepatocellular carcinoma. J Surg Res. 2015;198(1 ):73–79. doi:10.1016/j.jss.2015.05.00326022997
   PubMed Web of Science ®Google Scholar
• D’Emic N, Engelman A, Molitoris J, et al. Prognostic significance of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients treated with selective internal radiation therapy. J Gastrointest Oncol. 2016;7(2 ):269–277. doi:10.3978/j.issn.2078-6891.2015.10827034796
   PubMedGoogle Scholar
• Raben M, Walach N, Galili U, Schlesinger M. The effect of radiation therapy on lymphocyte subpopulations in cancer patients. Cancer-Am Cancer Soc. 1976;37(3 ):1417–1421.
   Google Scholar
• Ellsworth SG. Field size effects on the risk and severity of treatment-induced lymphopenia in patients undergoing radiation therapy for solid tumors. Adv Radiat Oncol. 2018;3(4 ):512–519. doi:10.1016/j.adro.2018.08.01430370350
   PubMedGoogle Scholar
• Venkatesulu BP, Mallick S, Lin SH, Krishnan S. A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors. Crit Rev Oncol Hematol. 2018;123:42–51. doi:10.1016/j.critrevonc.2018.01.00329482778
   PubMed Web of Science ®Google Scholar
• Maehata Y, Onishi H, Kuriyama K, et al. Immune responses following stereotactic body radiotherapy for stage I primary lung cancer. Biomed Res Int. 2013;2013:731346. doi:10.1155/2013/73134624324972
   PubMed Web of Science ®Google Scholar
• Grossman SA, Ye X, Lesser G, et al. Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res. 2011;17(16 ):5473–5480. doi:10.1158/1078-0432.CCR-11-077421737504
   PubMed Web of Science ®Google Scholar
• Budczies J, Klauschen F, Sinn BV, et al. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS ONE. 2012;7(12 ):e51862. doi:10.1371/journal.pone.005186223251644
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203 ):436–444. doi:10.1038/nature0720518650914
   PubMed Web of Science ®Google Scholar
• Zheng J, Cai J, Li H, et al. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio as prognostic predictors for hepatocellular carcinoma patients with various treatments: a meta-analysis and systematic review. Cell Physiol Biochem. 2017;44(3 ):967–981. doi:10.1159/00048539629179180
   PubMedGoogle Scholar
• Uchinaka E, Amisaki M, Morimoto M, et al. Utility and limitation of preoperative neutrophil lymphocyte ratio as a prognostic factor in hepatocellular carcinoma. Yonago Acta Med. 2018;61(4 ):197–203. doi:10.33160/yam.2018.12.00230636915
   PubMed Web of Science ®Google Scholar
• Lin WF, Zhong MF, Zhang YR, et al. Prognostic role of platelet-to-lymphocyte ratio in hepatocellular carcinoma with different BCLC stages: a systematic review and meta-analysis. Gastroenterol Res Pract. 2018;2018:5670949. doi:10.1155/2018/567094930158964
   PubMed Web of Science ®Google Scholar
• Son SH, Park EY, Park HH, Kay CS, Jang HS. Pre-radiotherapy neutrophil-to-lymphocyte ratio as an independent prognostic factor in patients with locally advanced hepatocellular carcinoma treated with radiotherapy. Oncotarget. 2017;8(10 ):16964–16971. doi:10.18632/oncotarget.v8i1028199977
   PubMedGoogle Scholar
• Dan J, Zhang Y, Peng Z, et al. Postoperative neutrophil-to-lymphocyte ratio change predicts survival of patients with small hepatocellular carcinoma undergoing radiofrequency ablation. PLoS ONE. 2013;8(3 ):e58184. doi:10.1371/journal.pone.005818423516447
   PubMed Web of Science ®Google Scholar
• Guo M, Li W, Li B, et al. Prognostic value of delta inflammatory biomarker-based nomograms in patients with inoperable locally advanced NSCLC. Int Immunopharmacol. 2019;72:395–401. doi:10.1016/j.intimp.2019.04.03231030095
   PubMed Web of Science ®Google Scholar
• Mazumdar M, Glassman JR. Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision-making about cancer treatments. Stat Med. 2000;19(1 ):113–132. doi:10.1002/(ISSN)1097-025810623917
   PubMed Web of Science ®Google Scholar
• Perkins NJ, Schisterman EF. The inconsistency of “optimal” cutpoints obtained using two criteria based on the receiver operating characteristic curve. Am J Epidemiol. 2006;163(7 ):670–675. doi:10.1093/aje/kwj06316410346
   PubMed Web of Science ®Google Scholar
• Kusumanto YH, Dam WA, Hospers GA, Meijer C, Mulder NH. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis. 2003;6(4 ):283–287. doi:10.1023/B:AGEN.0000029415.62384.ba15166496
   PubMedGoogle Scholar
• Li XF, Chen DP, Ouyang FZ, et al. Increased autophagy sustains the survival and pro-tumourigenic effects of neutrophils in human hepatocellular carcinoma. J Hepatol. 2015;62(1 ):131–139. doi:10.1016/j.jhep.2014.08.02325152203
   PubMed Web of Science ®Google Scholar
• Kim SJ, Davis RP, Jenne CN. Platelets as modulators of inflammation. Semin Thromb Hemost. 2018;44(2 ):91–101. doi:10.1055/s-0037-160743229165740
   PubMed Web of Science ®Google Scholar
• Nieswandt B, Hafner M, Echtenacher B, Mannel DN. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res. 1999;59:1295–1300.10096562
   PubMed Web of Science ®Google Scholar
• Mlecnik B, Tosolini M, Kirilovsky A, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol. 2011;29(6 ):610–618. doi:10.1200/JCO.2010.30.542521245428
   PubMed Web of Science ®Google Scholar
• Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21(2 ):137–148. doi:10.1016/j.immuni.2004.07.01715308095
   PubMed Web of Science ®Google Scholar